Andrew Kuykendall, MD, H. Lee Moffitt Cancer Center, Tampa, FL, comments on the direction in which myeloproliferative neoplasm (MPN) therapy is currently headed and the implications for MPN patients. Dr Kuykendall talks on the currently approved treatments ruxolitinib and fedratinib, and the patient subgroups whose clinical needs are not well served by JAK inhibition. Dr Kuykendall also talks about a potential shift in research focus which may be witnessed in the coming years, centered around early intervention in the chronic phases of MPNs to halt disease progression. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.